Results 191 to 200 of about 64,013 (258)

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber   +3 more
wiley   +1 more source

Gene Editing for Haemophilia—The Next Frontier

open access: yesHaemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti   +3 more
wiley   +1 more source

Severe hidradenitis suppurativa exacerbation in temporal association with PD‐1 blockade in cutaneous squamous cell carcinoma

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nadine Larissa Fergen   +4 more
wiley   +1 more source

Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg   +9 more
wiley   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz   +11 more
wiley   +1 more source

Small Bowel Lesions and Bleeding Risk in Hemodialysis Patients: A Narrative Review

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background Gastrointestinal bleeding is very common among hemodialysis patients. This high bleeding risk is caused by uremic platelet dysfunction, vascular fragility, intradialytic hemodynamic instability, and widespread antithrombotic therapy.
Andreas Smyrlis   +3 more
wiley   +1 more source

Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background Iron overload in chronic kidney disease contributes to oxidative injury. The role of iron chelators, standard in transfusion‐related overload, remains unclear in chronic kidney disease. Aim To evaluate the efficacy and safety of iron chelators in adults with chronic kidney disease.
Humam Emad Rajha   +6 more
wiley   +1 more source

Extended Double Plasma Molecular Adsorption Sessions and Bilirubin Clearance: A Case Report

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background The double plasma molecular adsorption system is an artificial‐liver treatment model combining the use of ion exchange resins and neutral microporous resins to remove toxins such as inflammatory cytokines without consuming large amounts of plasma and albumin. Given the relatively expensive consumables needed for Bilirubin adsorption,
Hui Ye   +7 more
wiley   +1 more source

Recombinant ADAMTS13 Ameliorates Liver Injury and Improves Hepatic Microcirculation in a Murine Acute‐on‐Chronic Liver Failure Model

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim The therapeutic significance of recombinant a disintegrin‐like and metalloprotease with thrombospondin type 1 motif 13 (rADAMTS13) in acute‐on‐chronic liver failure (ACLF) remains unclear. We aimed to investigate the therapeutic effects of rADAMTS13 in a murine model of ACLF‐like liver injury.
Jun‐ichi Hanatani   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy